3696 Stock Chart & Stats
HK$44.56
-HK$2.00(-4.17%)
At close: 4:00 PM EDT
HK$44.56
-HK$2.00(-4.17%)
Day’s Range― - ―
52-Week RangeHK$29.98 - HK$80.90
Previous CloseN/A
Volume13.12M
Average Volume (3M)37.74M
Market Cap
HK$26.21B
Enterprise ValueHK$17.33K
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.65
Shares Outstanding582,436,800
10 Day Avg. Volume37,735,340
30 Day Avg. Volume37,735,340
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.01
Revenue Forecast (FY)HK$179.72M
InSilico Medicine Cayman TopCo News
3696 FAQ
What was InSilico Medicine Cayman TopCo’s price range in the past 12 months?
InSilico Medicine Cayman TopCo lowest stock price was HK$29.98 and its highest was HK$80.90 in the past 12 months.
What is InSilico Medicine Cayman TopCo’s market cap?
InSilico Medicine Cayman TopCo’s market cap is HK$26.21B.
When is InSilico Medicine Cayman TopCo’s upcoming earnings report date?
InSilico Medicine Cayman TopCo’s upcoming earnings report date is Aug 26, 2026 which is in 7 days.
How were InSilico Medicine Cayman TopCo’s earnings last quarter?
InSilico Medicine Cayman TopCo released its earnings results on Mar 30, 2026. The company reported -HK$4.646 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is InSilico Medicine Cayman TopCo overvalued?
According to Wall Street analysts InSilico Medicine Cayman TopCo’s price is currently Overvalued.
Does InSilico Medicine Cayman TopCo pay dividends?
InSilico Medicine Cayman TopCo does not currently pay dividends.
What is InSilico Medicine Cayman TopCo’s EPS estimate?
InSilico Medicine Cayman TopCo’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InSilico Medicine Cayman TopCo have?
InSilico Medicine Cayman TopCo has 582,436,800 shares outstanding.
What happened to InSilico Medicine Cayman TopCo’s price movement after its last earnings report?
InSilico Medicine Cayman TopCo reported an EPS of -HK$4.646 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.622%.
Which hedge fund is a major shareholder of InSilico Medicine Cayman TopCo?
Currently, no hedge funds are holding shares in HK:3696
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
InSilico Medicine Cayman TopCo Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
240.94%
Trailing 12-Months
Company Description
InSilico Medicine Cayman TopCo
InSilico Medicine Cayman TopCo engages in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. The company offers Pharma.AI, an AI-powered drug discovery and development platform offering new target identification, small molecule generation, and clinical outcome prediction services. Its pipeline covers solutions for fibrosis, oncology, immunology, metabolic, anti-pain, and other therapeutic areas. The company is also involved in research and development collaboration, software solutions, business development, new drug discovery, and holding company businesses. The company has a strategic collaboration agreement with Suzhou Ribo Life Science Co., Ltd. for the development of oligonucleotide therapeutics; and strategic collaboration with Human Life Foundation Models, Inc. for the development of foundation models for human longevity science. It operates in Hong Kong, the United States, the United Kingdom, Kingdom of Saudi Arabia, Japan, Denmark, the United Arab Emirates, Korea, Mainland China, Germany, Switzerland, Taiwan, and internationally. The company was founded in 2014 and is based in New Territories, Hong Kong.
Century Sage Scientific Holdings Ltd
―
AInnovation Technology Group
―
Beijing Fourth Paradigm Technology Co. Ltd. Class H
―
Beijing Saimo Technology Co. Ltd. Class H
―
Unisound AI Technology Co., Ltd.
―